Business Description
CardieX Ltd
ISIN : AU0000015729
Description
CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.09 | |||||
| Debt-to-Equity | 388.5 | |||||
| Debt-to-EBITDA | -1 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -11.46 | |||||
| Beneish M-Score | -4.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.5 | |||||
| 3-Year EBITDA Growth Rate | -52.2 | |||||
| 3-Year EPS without NRI Growth Rate | -46.9 | |||||
| 3-Year FCF Growth Rate | -53.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.56 | |||||
| 9-Day RSI | 14.67 | |||||
| 14-Day RSI | 18.21 | |||||
| 6-1 Month Momentum % | -37.08 | |||||
| 12-1 Month Momentum % | -77.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.85 | |||||
| Cash Ratio | 0.65 | |||||
| Days Inventory | 744.36 | |||||
| Days Sales Outstanding | 31.71 | |||||
| Days Payable | 2374.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24 | |||||
| Shareholder Yield % | -53.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.76 | |||||
| Operating Margin % | -77.59 | |||||
| Net Margin % | -74.45 | |||||
| FCF Margin % | -42.83 | |||||
| ROE % | -739.24 | |||||
| ROA % | -61.91 | |||||
| ROIC % | -110.48 | |||||
| ROC (Joel Greenblatt) % | -658.67 | |||||
| ROCE % | -334.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.73 | |||||
| EV-to-EBIT | -1.95 | |||||
| EV-to-EBITDA | -1.95 | |||||
| EV-to-Revenue | 1.32 | |||||
| EV-to-FCF | -3.29 | |||||
| Price-to-Median-PS-Value | 0.45 | |||||
| Earnings Yield (Greenblatt) % | -51.24 | |||||
| FCF Yield % | -31.18 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers